Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

Patient-specific intervention enhances anticoagulation therapy

09 Aug 2017

Interventions specifically tailored to patients with heart failure significantly improve anticoagulation therapy, suggests a recent study.

To examine the effect of a patient-specific tailored intervention on anticoagulation control, researchers randomly assigned patients with heart failure taking warfarin therapy (n=145) to either standard care or a one-time intervention assessing potential risk factors for lability of international normalized ratio (INR), in which they received specific instructions. They then assessed time in therapeutic range (TTR) using Rosendaal’s linear model 3 months before and after the intervention.

Anticoagulation control was significantly increased with the patient-specific tailored intervention. Prior to intervention, the median TTR levels were suboptimal in the interventional and control groups (53 vs 45 percent; p=0.14). After the intervention, the median TTR rose significantly in the interventional group compared with the control group (80 [interquartile range, 62 to 93 percent] vs 44 percent [29 to 61 percent]; p<0.0001).

The patient-tailored intervention led to a significant improvement in the interventional group before vs after intervention (53 vs 80 percent; p<0.0001) but not in the control group (45 vs 44 percent; p=0.95). The interventional group also had substantially higher percentage of patients with a TTR ≥60 percent, considered therapeutic, than the control group (79 vs 25 percent; p<0.0001).

After intervention, the interventional group, but not the control group, had a significantly reduced INR variability (standard deviation of each patient’s INR measurements) from 0.53 to 0.32 (p<0.0001).

“Many patients with heart failure need anticoagulants, including warfarin,” researchers said. “Good control is particularly challenging in heart failure patients, with <60 percent of INR measurements in the therapeutic range, thereby increasing the risk of complications.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 18 Feb 2016
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
01 Apr 2016
Amiodarone is safe and effective for early junctional ectopic tachycardia prophylaxis in paediatric patients following open heart surgery, based on a study.
Tristan Manalac, 19 May 2018
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.